secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioAtla, Inc. (BCAB)
CIK:        0001826892
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0000950170-24-059508
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioAtla Q1 net loss $23.2M, cash $80.6M; positive Phase 2 data for ozuriftamab vedotin and evalstotug
--------------------------------------------------------------------------------

- Net loss $23.2M in Q1 2024 vs $27.5M in Q1 2023; cash $80.6M as of March 31, 2024.
- Ozuriftamab vedotin in SCCHN: 11 total responses (5 confirmed incl. 1 CR), 86% DCR; FDA meeting for potential registrational trial expected 2H 2024.
- Evalstotug: DLT clearance at 1 gram in 2Q 2024; Phase 2 monotherapy data 2Q 2024; FDA meeting for BRAF-mutated melanoma registrational trial in 2H 2024.
- Mecbotamab vedotin in UPS: initial 20 patients enrolled; FDA meeting for remaining trial portion 2H 2024.
- CAB-Nectin4-ADC (BA3361) received FDA IND clearance in May 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826892/000095017024059508/0000950170-24-059508-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826892/000095017024059508/bcab-20240514.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-059508

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer